AST in Medical Technology

Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

... trials." In the 75 and 100 mg/day cohorts, patients receiving IDX184 experienced improvements in two key markers of liver injury, with mean ast and ALT levels decreasing to below the upper limit of normal. These improvements were sustained for up to 6 days post-dosing, and most levels returned...

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)

...abnormalities were noted slightly more frequently in patients treated with pirfenidone (phosphate elevation, hyponatremia, lymphopenia, ALT elevation, ast elevation and cholesterol elevation). Of these laboratory abnormalities in pirfenidone patients, all but one case each of hyponatremia and lymphopeni...

CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis

...eks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Should an increase in ALT or ast of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who consume sub...

CRESTOR(R) Reduced Risk of Blood Clots in the Veins

...eks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Should an increase in ALT or ast of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who consume sub...

Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)

...following statements: Raptor's and UC San Diego's ability to complete the clinical trial in NASH patients, cysteamine's ability to treat NASH, ALT and ast as a biomarker to determine the efficacy of a treatment for NASH, Raptor's ability to further develop cysteamine in NASH and other indications. These ...

Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial

... headache and vomiting (limited duration and amenable to supportive care). The few drug-related Grade 3 and 4 toxicities (including fatigue, increased ast and headache, two patients each) were manageable and only one patient discontinued treatment for an adverse event. Noticeably absent were toxicities c...

New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens

...on adverse events (AEs) in the combination arm versus the monotherapy arm were diarrhea (67 percent vs. 58 percent), rash (28 percent vs. 29 percent), ast increase (32 percent vs. 16 percent), ALT increase (30 percent vs. 16 percent), nausea (29 percent vs. 16 percent), hypertension (26 percent vs. 4 per...

New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma

...3%), elevated alkaline phosphatase (68%), elevated serum creatinine (57%), lymphopenia (53%), hypophosphatemia (49%), thrombocytopenia (40%), elevated ast (38%), and leukopenia (32%). Most common Grades 3/4 adverse events included asthenia (11%), dyspnea (9%), hemoglobin decreased (20%), lymphocytes de...

New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer

...3%), elevated alkaline phosphatase (68%), elevated serum creatinine (57%), lymphopenia (53%), hypophosphatemia (49%), thrombocytopenia (40%), elevated ast (38%), and leukopenia (32%). Most common Grades 3/4 adverse events included asthenia (11%), dyspnea (9%), hemoglobin decreased (20%), lymphocytes de...

Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer

...3%), elevated alkaline phosphatase (68%), elevated serum creatinine (57%), lymphopenia (53%), hypophosphatemia (49%), thrombocytopenia (40%), elevated ast (38%), and leukopenia (32%). Most common grades 3/4 adverse events included asthenia (11%), dyspnea (9%), hemoglobin decreased (20%), lymphocytes decr...

CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients

...Grade 3-4 ALT elevations: 2% in the once-daily REYATAZ(R) (atazanavir sulfate)/r arm vs. 1% in the twice-daily lopinavir/r arm -- Grade 3-4 ast elevations: 2% in the REYATAZ/r arm vs. less than 1% in the lopinavir/r arm A prespecified descriptive analysis of virologic response rates (...

Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer

...3%), elevated alkaline phosphatase (68%), elevated serum creatinine (57%), lymphopenia (53%), hypophosphatemia (49%), thrombocytopenia (40%), elevated ast (38%), and leukopenia (32%). Most common grades 3/4 adverse events included asthenia (11%), dyspnea (9%), hemoglobin decreased (20%), lymphocytes de...

Updated Phase 1 Data for Exelixis' XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity

...e 2 program by the end of 2007." To date, five dose-limiting toxicities (DLTs) have been reported, including Grade 3 palmar/plantar erythema, Grade 3 ast elevation, Grade 3 ALT elevation, and Grade 3 lipase elevation in patients dosed at 11.52 mg/kg, as well as a DLT of Grade 2 mucositis in a patient do...

New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile

... echinocandins, specifically MYCAMINE: A Proposal for an Antifungal Susceptibility Testing (AST) Breakpoint of Micafungin and Candida: Integration of ast Surveys and Correlation with Clinical Outcomes In this study, investigators looked at two large, well-known medical databases to determine if candida...

Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer Treatment

...ancer were neutropenia (24%-26%); alkaline phosphatase elevation (16%-20%); ast elevation (12%-17%); nausea/vomiting (12%-13%); ALT elevation (10%-11%); an...(4%-8%); and pain (2%-7%). The most common adverse events (all grades) were ast (72%-78%); alkaline phosphatase (71%-77%); anemia (65%-73%); ALT (72%); leu...